Oxidative  ||| S:0 E:10 ||| JJ
stress  ||| S:10 E:17 ||| NN
and  ||| S:17 E:21 ||| CC
antioxidant  ||| S:21 E:33 ||| FW
status  ||| S:33 E:40 ||| FW
in  ||| S:40 E:43 ||| FW
intensely  ||| S:43 E:53 ||| FW
exercising  ||| S:53 E:64 ||| FW
horses  ||| S:64 E:71 ||| FW
administered  ||| S:71 E:84 ||| FW
nutraceutical  ||| S:84 E:98 ||| FW
extracts  ||| S:98 E:107 ||| FW
Many  ||| S:107 E:112 ||| JJ
nutraceuticals  ||| S:112 E:127 ||| NNS
are  ||| S:127 E:131 ||| VBP
used  ||| S:131 E:136 ||| VBN
as  ||| S:136 E:139 ||| IN
equine  ||| S:139 E:146 ||| JJ
supplements  ||| S:146 E:158 ||| NN
without  ||| S:158 E:166 ||| IN
their  ||| S:166 E:172 ||| PRP$
efficacy  ||| S:172 E:181 ||| NN
having  ||| S:181 E:188 ||| VBG
been  ||| S:188 E:193 ||| VBN
scientifically  ||| S:193 E:208 ||| RB
tested ||| S:208 E:214 ||| VBN
.  ||| S:214 E:216 ||| .
Black  ||| S:216 E:222 ||| JJ
tea ||| S:222 E:225 ||| NN
,  ||| S:225 E:227 ||| ,
cranberries ||| S:227 E:238 ||| NN
,  ||| S:238 E:240 ||| ,
orange  ||| S:240 E:247 ||| JJ
peel  ||| S:247 E:252 ||| NN
and  ||| S:252 E:256 ||| CC
ginger  ||| S:256 E:263 ||| NNS
are  ||| S:263 E:267 ||| VBP
a  ||| S:267 E:269 ||| DT
few  ||| S:269 E:273 ||| JJ
of  ||| S:273 E:276 ||| IN
those  ||| S:276 E:282 ||| DT
nutraceuticals  ||| S:282 E:297 ||| NN
that  ||| S:297 E:302 ||| WDT
warrant  ||| S:302 E:310 ||| VBP
further  ||| S:310 E:318 ||| JJ
study ||| S:318 E:323 ||| NN
.  ||| S:323 E:325 ||| .
To  ||| S:325 E:328 ||| TO
test  ||| S:328 E:333 ||| VB
the  ||| S:333 E:337 ||| DT
effects  ||| S:337 E:345 ||| NNS
of  ||| S:345 E:348 ||| IN
single  ||| S:348 E:355 ||| JJ
doses  ||| S:355 E:361 ||| NNS
of  ||| S:361 E:364 ||| IN
black  ||| S:364 E:370 ||| JJ
tea ||| S:370 E:373 ||| NN
,  ||| S:373 E:375 ||| ,
cranberry ||| S:375 E:384 ||| NN
,  ||| S:384 E:386 ||| ,
orange  ||| S:386 E:393 ||| JJ
peel  ||| S:393 E:398 ||| NN
and  ||| S:398 E:402 ||| CC
ginger  ||| S:402 E:409 ||| JJ
extract  ||| S:409 E:417 ||| NN
on  ||| S:417 E:420 ||| IN
markers  ||| S:420 E:428 ||| NN
of  ||| S:428 E:431 ||| IN
oxidative  ||| S:431 E:441 ||| JJ
stress  ||| S:441 E:448 ||| NN
and  ||| S:448 E:452 ||| CC
antioxidant  ||| S:452 E:464 ||| JJ
status  ||| S:464 E:471 ||| NN
following  ||| S:471 E:481 ||| VBG
exercise  ||| S:481 E:490 ||| NN
in  ||| S:490 E:493 ||| IN
horses ||| S:493 E:499 ||| NNS
.  ||| S:499 E:501 ||| .
In  ||| S:501 E:504 ||| IN
Study  ||| S:504 E:510 ||| NNP
1 ||| S:510 E:511 ||| CD
,  ||| S:511 E:513 ||| ,
9  ||| S:513 E:515 ||| CD
mature ||| S:515 E:521 ||| NN
,  ||| S:521 E:523 ||| ,
healthy  ||| S:523 E:531 ||| JJ
but  ||| S:531 E:535 ||| CC
unfit  ||| S:535 E:541 ||| JJ
Standardbred  ||| S:541 E:554 ||| JJ
mares  ||| S:554 E:560 ||| NN
were  ||| S:560 E:565 ||| VBD
administered  ||| S:565 E:578 ||| VBN
2  ||| S:578 E:580 ||| CD
l  ||| S:580 E:582 ||| NN
of  ||| S:582 E:585 ||| IN
a  ||| S:585 E:587 ||| DT
control  ||| S:587 E:595 ||| NN
( ||| S:595 E:596 ||| -LRB-
water ||| S:596 E:601 ||| NN
) ||| S:601 E:602 ||| -RRB-
,  ||| S:602 E:604 ||| ,
orange  ||| S:604 E:611 ||| FW
peel  ||| S:611 E:616 ||| FW
extract  ||| S:616 E:624 ||| FW
( ||| S:624 E:625 ||| -LRB-
30  ||| S:625 E:628 ||| CD
g  ||| S:628 E:630 ||| CD
extract ||| S:630 E:637 ||| CD
)  ||| S:637 E:639 ||| -RRB-
or  ||| S:639 E:642 ||| CC
decaffeinated  ||| S:642 E:656 ||| JJ
black  ||| S:656 E:662 ||| JJ
tea  ||| S:662 E:666 ||| NN
extract  ||| S:666 E:674 ||| NNS
( ||| S:674 E:675 ||| -LRB-
28  ||| S:675 E:678 ||| CD
g  ||| S:678 E:680 ||| CD
extract ||| S:680 E:687 ||| CD
) ||| S:687 E:688 ||| -RRB-
.  ||| S:688 E:690 ||| .
In  ||| S:690 E:693 ||| IN
Study  ||| S:693 E:699 ||| NNP
2  ||| S:699 E:701 ||| CD
the  ||| S:701 E:705 ||| DT
same  ||| S:705 E:710 ||| JJ
mares  ||| S:710 E:716 ||| NN
were  ||| S:716 E:721 ||| VBD
administered  ||| S:721 E:734 ||| VBN
2  ||| S:734 E:736 ||| CD
l  ||| S:736 E:738 ||| NN
of  ||| S:738 E:741 ||| IN
a  ||| S:741 E:743 ||| DT
control  ||| S:743 E:751 ||| NN
( ||| S:751 E:752 ||| -LRB-
water ||| S:752 E:757 ||| NN
) ||| S:757 E:758 ||| -RRB-
,  ||| S:758 E:760 ||| ,
cranberry  ||| S:760 E:770 ||| RB
extract  ||| S:770 E:778 ||| VB
( ||| S:778 E:779 ||| -LRB-
30  ||| S:779 E:782 ||| CD
g  ||| S:782 E:784 ||| CD
extract ||| S:784 E:791 ||| CD
)  ||| S:791 E:793 ||| -RRB-
or  ||| S:793 E:796 ||| CC
ginger  ||| S:796 E:803 ||| JJ
extract  ||| S:803 E:811 ||| NNS
( ||| S:811 E:812 ||| -LRB-
30  ||| S:812 E:815 ||| CD
g  ||| S:815 E:817 ||| CD
extract ||| S:817 E:824 ||| CD
) ||| S:824 E:825 ||| -RRB-
.  ||| S:825 E:827 ||| .
In  ||| S:827 E:830 ||| IN
each  ||| S:830 E:835 ||| DT
study ||| S:835 E:840 ||| NN
,  ||| S:840 E:842 ||| ,
mares  ||| S:842 E:848 ||| NN
were  ||| S:848 E:853 ||| VBD
given  ||| S:853 E:859 ||| VBN
the  ||| S:859 E:863 ||| DT
extracts  ||| S:863 E:872 ||| NN
via  ||| S:872 E:876 ||| IN
nasogastric  ||| S:876 E:888 ||| JJ
tube  ||| S:888 E:893 ||| NN
1  ||| S:893 E:895 ||| CD
h  ||| S:895 E:897 ||| NN
before  ||| S:897 E:904 ||| IN
performing  ||| S:904 E:915 ||| VBG
a  ||| S:915 E:917 ||| DT
graded  ||| S:917 E:924 ||| JJ
exercise  ||| S:924 E:933 ||| NN
test  ||| S:933 E:938 ||| NN
( ||| S:938 E:939 ||| -LRB-
GXT ||| S:939 E:942 ||| NNP
) ||| S:942 E:943 ||| -RRB-
,  ||| S:943 E:945 ||| ,
in  ||| S:945 E:948 ||| IN
a  ||| S:948 E:950 ||| DT
randomised  ||| S:950 E:961 ||| JJ
crossover  ||| S:961 E:971 ||| JJ
design  ||| S:971 E:978 ||| NN
with  ||| S:978 E:983 ||| IN
at  ||| S:983 E:986 ||| IN
least  ||| S:986 E:992 ||| JJS
7  ||| S:992 E:994 ||| CD
days  ||| S:994 E:999 ||| NNS
between  ||| S:999 E:1007 ||| IN
GXTs ||| S:1007 E:1011 ||| JJ
.  ||| S:1011 E:1013 ||| .
Blood  ||| S:1013 E:1019 ||| NN
samples  ||| S:1019 E:1027 ||| NNS
were  ||| S:1027 E:1032 ||| VBD
collected  ||| S:1032 E:1042 ||| VBN
at  ||| S:1042 E:1045 ||| IN
rest ||| S:1045 E:1049 ||| NN
,  ||| S:1049 E:1051 ||| ,
at  ||| S:1051 E:1054 ||| IN
fatigue ||| S:1054 E:1061 ||| NN
,  ||| S:1061 E:1063 ||| ,
and  ||| S:1063 E:1067 ||| CC
1  ||| S:1067 E:1069 ||| CD
and  ||| S:1069 E:1073 ||| CC
24  ||| S:1073 E:1076 ||| CD
h  ||| S:1076 E:1078 ||| JJ
post  ||| S:1078 E:1083 ||| NN
exercise  ||| S:1083 E:1092 ||| NN
and  ||| S:1092 E:1096 ||| CC
analysed  ||| S:1096 E:1105 ||| NN
for  ||| S:1105 E:1109 ||| IN
lipid  ||| S:1109 E:1115 ||| JJ
hydroperoxides  ||| S:1115 E:1130 ||| NNS
( ||| S:1130 E:1131 ||| -LRB-
LPO ||| S:1131 E:1134 ||| NNP
) ||| S:1134 E:1135 ||| -RRB-
,  ||| S:1135 E:1137 ||| ,
total  ||| S:1137 E:1143 ||| JJ
glutathione  ||| S:1143 E:1155 ||| NNS
( ||| S:1155 E:1156 ||| -LRB-
GSH-T ||| S:1156 E:1161 ||| NNP
) ||| S:1161 E:1162 ||| -RRB-
,  ||| S:1162 E:1164 ||| ,
glutathione  ||| S:1164 E:1176 ||| FW
peroxidase  ||| S:1176 E:1187 ||| FW
( ||| S:1187 E:1188 ||| -LRB-
GPx ||| S:1188 E:1191 ||| NNP
) ||| S:1191 E:1192 ||| -RRB-
,  ||| S:1192 E:1194 ||| ,
α-tocopherol  ||| S:1194 E:1207 ||| NNP
( ||| S:1207 E:1208 ||| -LRB-
TOC ||| S:1208 E:1211 ||| NNP
) ||| S:1211 E:1212 ||| -RRB-
,  ||| S:1212 E:1214 ||| ,
β-carotene  ||| S:1214 E:1225 ||| NNP
( ||| S:1225 E:1226 ||| -LRB-
BC ||| S:1226 E:1228 ||| NNP
)  ||| S:1228 E:1230 ||| -RRB-
and  ||| S:1230 E:1234 ||| CC
retinol ||| S:1234 E:1241 ||| NN
.  ||| S:1241 E:1243 ||| .
Data  ||| S:1243 E:1248 ||| NNP
were  ||| S:1248 E:1253 ||| VBD
statistically  ||| S:1253 E:1267 ||| RB
analysed  ||| S:1267 E:1276 ||| VBP
using  ||| S:1276 E:1282 ||| VBG
a  ||| S:1282 E:1284 ||| DT
repeated  ||| S:1284 E:1293 ||| NN
measures  ||| S:1293 E:1302 ||| VBZ
ANOVA ||| S:1302 E:1307 ||| NNP
.  ||| S:1307 E:1309 ||| .
In  ||| S:1309 E:1312 ||| IN
Study  ||| S:1312 E:1318 ||| NNP
1  ||| S:1318 E:1320 ||| CD
there  ||| S:1320 E:1326 ||| RB
was  ||| S:1326 E:1330 ||| VBD
no  ||| S:1330 E:1333 ||| DT
effect  ||| S:1333 E:1340 ||| NN
of  ||| S:1340 E:1343 ||| IN
treatment  ||| S:1343 E:1353 ||| NN
for  ||| S:1353 E:1357 ||| IN
LPO ||| S:1357 E:1360 ||| NNP
,  ||| S:1360 E:1362 ||| ,
GSH-T ||| S:1362 E:1367 ||| NNP
,  ||| S:1367 E:1369 ||| ,
GPx ||| S:1369 E:1372 ||| NNP
,  ||| S:1372 E:1374 ||| ,
TOC  ||| S:1374 E:1378 ||| NNP
or  ||| S:1378 E:1381 ||| CC
BC ||| S:1381 E:1383 ||| NNP
.  ||| S:1383 E:1385 ||| .
Retinol  ||| S:1385 E:1393 ||| NNP
was  ||| S:1393 E:1397 ||| VBD
higher  ||| S:1397 E:1404 ||| JJR
for  ||| S:1404 E:1408 ||| IN
both  ||| S:1408 E:1413 ||| DT
tea  ||| S:1413 E:1417 ||| NN
( ||| S:1417 E:1418 ||| -LRB-
P  ||| S:1418 E:1420 ||| NN
=  ||| S:1420 E:1422 ||| SYM
0.0006 ||| S:1422 E:1428 ||| CD
)  ||| S:1428 E:1430 ||| -RRB-
and  ||| S:1430 E:1434 ||| CC
water  ||| S:1434 E:1440 ||| NN
( ||| S:1440 E:1441 ||| -LRB-
P  ||| S:1441 E:1443 ||| NN
=  ||| S:1443 E:1445 ||| SYM
0.004 ||| S:1445 E:1450 ||| CD
)  ||| S:1450 E:1452 ||| -RRB-
than  ||| S:1452 E:1457 ||| IN
for  ||| S:1457 E:1461 ||| IN
orange  ||| S:1461 E:1468 ||| JJ
peel ||| S:1468 E:1472 ||| NN
.  ||| S:1472 E:1474 ||| .
In  ||| S:1474 E:1477 ||| IN
Study  ||| S:1477 E:1483 ||| NNP
2  ||| S:1483 E:1485 ||| ,
there  ||| S:1485 E:1491 ||| EX
was  ||| S:1491 E:1495 ||| VBD
no  ||| S:1495 E:1498 ||| DT
treatment  ||| S:1498 E:1508 ||| NN
effect  ||| S:1508 E:1515 ||| NN
for  ||| S:1515 E:1519 ||| IN
LPO ||| S:1519 E:1522 ||| NNP
,  ||| S:1522 E:1524 ||| ,
GPx ||| S:1524 E:1527 ||| NNP
,  ||| S:1527 E:1529 ||| ,
GSH-T ||| S:1529 E:1534 ||| NNP
,  ||| S:1534 E:1536 ||| ,
RET ||| S:1536 E:1539 ||| NNP
,  ||| S:1539 E:1541 ||| ,
BC  ||| S:1541 E:1544 ||| NNP
or  ||| S:1544 E:1547 ||| CC
TOC ||| S:1547 E:1550 ||| NNP
.  ||| S:1550 E:1552 ||| .
The  ||| S:1552 E:1556 ||| DT
results  ||| S:1556 E:1564 ||| NNS
show  ||| S:1564 E:1569 ||| VBP
that  ||| S:1569 E:1574 ||| IN
a  ||| S:1574 E:1576 ||| DT
single  ||| S:1576 E:1583 ||| JJ
dose  ||| S:1583 E:1588 ||| NN
of  ||| S:1588 E:1591 ||| IN
various  ||| S:1591 E:1599 ||| JJ
nutraceuticals  ||| S:1599 E:1614 ||| NN
in  ||| S:1614 E:1617 ||| IN
exercising  ||| S:1617 E:1628 ||| VBG
horses  ||| S:1628 E:1635 ||| NNS
do  ||| S:1635 E:1638 ||| VBP
not  ||| S:1638 E:1642 ||| RB
produce  ||| S:1642 E:1650 ||| VB
an  ||| S:1650 E:1653 ||| DT
effect  ||| S:1653 E:1660 ||| NN
on  ||| S:1660 E:1663 ||| IN
either  ||| S:1663 E:1670 ||| DT
oxidative  ||| S:1670 E:1680 ||| JJ
stress  ||| S:1680 E:1687 ||| NN
or  ||| S:1687 E:1690 ||| CC
antioxidant  ||| S:1690 E:1702 ||| JJ
status  ||| S:1702 E:1709 ||| NN
and  ||| S:1709 E:1713 ||| CC
further  ||| S:1713 E:1721 ||| JJ
investigation  ||| S:1721 E:1735 ||| NN
is  ||| S:1735 E:1738 ||| VBZ
needed  ||| S:1738 E:1745 ||| VBN
as  ||| S:1745 E:1748 ||| RB
to  ||| S:1748 E:1751 ||| TO
whether  ||| S:1751 E:1759 ||| IN
long-term  ||| S:1759 E:1769 ||| JJ
supplementation  ||| S:1769 E:1785 ||| NN
would  ||| S:1785 E:1791 ||| MD
enhance  ||| S:1791 E:1799 ||| VB
these  ||| S:1799 E:1805 ||| DT
effects ||| S:1805 E:1812 ||| NNS
.  ||| S:1812 E:1814 ||| .
